Bicara Therapeutics Inc. Common Stock (BCAX) - Stock Analysis
Last updated: Sep 13, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
BCAX has materially extended its cash runway via a ~$172.5M equity raise and is entering a data-rich 2026 with positive Phase 1b signals and multiple planned FORTIFI-HN01/expansion cohort updates; after a ~20% 21-day rise and clear clinical catalyst calendar, it offers a speculative event-driven upside opportunity in the very near term.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong Liquidity ⢠Low Leverage ⢠Ongoing Cash Burn BCAX has strong liquidity and low debt, but its lack of revenue, persistent losses, and cash burn make the premium-to-book valuation high risk.
Price Behavior
Key Price Behavior Insights: ⢠Lower highs ⢠Support test ⢠Weak momentum Support Level: $22.80â$23.10 Resistance Level: $23.60â$23.70 BCAX remains bearish over the last month below its moving average, with $22.80â$23.10 support critical; a break below it risks further downside, while reclaiming $23.60â$23.70 would improve momentum.
Sentiment & News
Key News Insights: ⢠Stake Increased ⢠CFO Incentive ⢠Hiring Expansion Bicara's expanded institutional ownership and inducement equity grants signal investor confidence and active talent recruitment.
AI Summary
BCAX is a well-funded, pre-revenue oncology optionânot an earnings storyâwhere its ~$497M cash balance funds near-term trial execution, but durable upside depends almost entirely on differentiated clinical data before cash burn and equity dilution force another raise; investors should await pipeline validation and watch $22.8 support, with a move above $24.6-$24.9 offering stronger confirmation.
Description
Bicara Therapeutics Inc. is a clinical-stage biopharmaceutical company developing bifunctional therapies for solid tumors. Its lead candidate, ficerafusp alfa, is a bifunctional antibody that combines an EGFR-targeting monoclonal antibody with a domain that binds TGF-β. Founded in 2018 and based in Boston, the company is a subsidiary of Biocon Limited.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Mar 19 | Mar 26 | BCAX | Bicara Therapeutics Inc. Common Stock | BCAX has materially extended its cash runway via a ~$172.5M equity raise and is entering a data-rich 2026 with positive Phase 1b signals and multiple planned FORTIFI-HN01/expansion cohort updates; after a ~20% 21-day rise and clear clinical catalyst calendar, it offers a speculative event-driven upside opportunity in the very near term. | Closed | +0.7% |